Pfizer Inc. (NYSE:PFE) Shares Acquired by Trust Co. of Toledo NA OH

Trust Co. of Toledo NA OH increased its position in shares of Pfizer Inc. (NYSE:PFE) by 7.5% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 154,346 shares of the biopharmaceutical company’s stock after purchasing an additional 10,713 shares during the quarter. Trust Co. of Toledo NA OH’s holdings in Pfizer were worth $3,911,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Rialto Wealth Management LLC acquired a new stake in shares of Pfizer during the fourth quarter worth about $26,000. Clarity Asset Management Inc. acquired a new stake in shares of Pfizer during the fourth quarter worth about $27,000. Gould Capital LLC lifted its holdings in shares of Pfizer by 97.2% during the fourth quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 493 shares during the period. Kohmann Bosshard Financial Services LLC acquired a new stake in shares of Pfizer during the fourth quarter worth about $28,000. Finally, Bernard Wealth Management Corp. acquired a new stake in shares of Pfizer during the fourth quarter worth about $30,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Stock Down 1.3%

Pfizer stock opened at $24.51 on Friday. The stock has a market capitalization of $139.35 billion, a PE ratio of 17.38, a price-to-earnings-growth ratio of 0.64 and a beta of 0.57. Pfizer Inc. has a 12 month low of $20.92 and a 12 month high of $31.54. The business has a 50 day simple moving average of $23.06 and a 200-day simple moving average of $24.95. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 EPS for the quarter, beating analysts’ consensus estimates of $0.67 by $0.25. The business had revenue of $13.72 billion during the quarter, compared to analysts’ expectations of $14.43 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The business’s revenue was down 7.8% compared to the same quarter last year. During the same period in the previous year, the business earned $0.82 earnings per share. On average, analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Friday, June 13th. Investors of record on Friday, May 9th were given a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 7.02%. The ex-dividend date was Friday, May 9th. Pfizer’s payout ratio is 124.64%.

Analyst Ratings Changes

A number of research firms recently commented on PFE. Guggenheim reaffirmed a “buy” rating on shares of Pfizer in a report on Tuesday, March 18th. Cantor Fitzgerald began coverage on Pfizer in a research report on Tuesday, April 22nd. They set a “neutral” rating and a $24.00 price target for the company. UBS Group lifted their price target on Pfizer from $24.00 to $25.00 and gave the company a “neutral” rating in a research report on Wednesday, April 30th. Hsbc Global Res upgraded Pfizer to a “strong-buy” rating in a research report on Monday, March 10th. Finally, Citigroup reiterated a “neutral” rating on shares of Pfizer in a research report on Thursday, March 27th. One research analyst has rated the stock with a sell rating, eight have given a hold rating, four have given a buy rating and three have issued a strong buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $29.17.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.